United Kingdom Hormonal Contraceptive Market Insight
The United Kingdom Hormonal Contraceptive Market is growing at an 1.93% CAGR, driven by reproductive health awareness, female workforce growth, delayed pregnancies, NHS support, and advanced LARCs improving efficacy and compliance.
United Kingdom Hormonal Contraceptive Market Insights Forecasts to 2035
- The United KingdomHormonal Contraceptive Market Size Was Estimated at USD 419.4Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 1.93% from 2025 to 2035
- The United KingdomHormonal Contraceptive Market Size is Expected to Reach USD 507.6Million by 2035
Notable Insights for United Kingdom Hormonal Contraceptive Market
- By product type, oral contraceptive pills dominate, accounting for approximately 45–50% share due to high awareness and ease of use
- Long-acting reversible contraceptives (implants and IUDs) account for around 35–40% share, showing rapid growth
- Approximately 70–75% of UK women of reproductive age have used hormonal contraception at least once
- Around 60–65% of contraceptiveusers prefer long-acting or low-maintenance hormonal methods for convenience
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Hormonal Contraceptive Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Hormonal Contraceptive Market
- Bayer
- Pfizer
- Organon
- Abbott
- Teva Pharmaceutical Industries
- GlaxoSmithKline
- Merck & Co.
- Janssen Pharmaceuticals
- Others
Recent Developments:
- In October 2025, Digital integration for contraception access: UK partnerships enabled cycle-tracking app Clue to support NHS-funded contraceptive access, improving digital delivery of hormonal contraception services and patient convenience.
- In December 2023, NHS Pharmacy Contraception Serviceenables community pharmacists in the UK to initiate and supply oral contraceptives, improving access and reducing GP workload.
- In June 2023, Non-hormonal male contraceptive trial: UK Phase 1 studies evaluated YCT-529, an oral vitamin A pathway inhibitor, offering a reversible hormone-free alternative to traditional contraception methods.
Market Segmentation:
United Kingdom Hormonal Contraceptive Market, By Product Type
- Oral Contraceptive Pills
- Hormonal Intrauterine Devices (IUDs/IUS)
- Contraceptive Implants
- Contraceptive Patches
- Injectable Hormonal Contraceptives
- Others
United Kingdom Hormonal Contraceptive Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Gynecology Centers
- Family Planning Centers
United Kingdom Hormonal Contraceptive Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
- NHS Clinics
Expert Views:
The UK hormonal contraceptive market is expected to grow steadily due to increasing preference for reliable and long-term birth control options and strong NHS-backed reproductive health programs. Experts highlight that long-acting reversible contraceptives will continue to gain dominance, supported by improved patient adherence and reduced failure rates compared to daily oral contraceptives. Continued innovation in hormone delivery systems and low-dose formulations is expected to further enhance safety, convenience, and market expansion through 2035.